Protein C Deficiency and Purpura Fulminans Information

Resources for healthcare professionals

The following societies can help healthcare professionals who seek more information about Protein C deficiency, purpura fulminans, venous thromboembolism, and the management of severe congenital Protein C deficiency when symptoms present in neonates, children, and adults.

Professional societies

American Academy of

American Society of

American Society of Pediatric Hematology/


National Heart, Lung, and Blood

National Organization for Rare Disorders (NORD)

Indication and Important Safety Information

  • Hypersensitivity/Allergic reactionsCEPROTIN® [Protein C Concentrate (Human)] may contain trace amounts of mouse protein and/or heparin as a result of the manufacturing process. Allergic reactions to mouse protein and/or heparin cannot be ruled out. In case of hypersensitivity/allergic reaction, discontinue CEPROTIN administration immediately and institute appropriate treatment.
  • Transmission of infectious agentsCEPROTIN is made from human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
  • Bleeding episodesSeveral bleeding episodes have been observed in clinical studies. Concurrent anticoagulant medication may have been responsible for these bleeding episodes. CEPROTIN administration may have further contributed to these bleeding events. Simultaneous administration of CEPROTIN and tissue plasminogen activator (tPA) may further increase the risk of bleeding from tPA.
  • Heparin-induced thrombocytopenia (HIT)CEPROTIN contains trace amounts of heparin that may lead to HIT, which can be associated with a rapid decrease of thrombocytes. If HIT is suspected, determine the platelet count immediately and discontinue CEPROTIN administration.
  • Low sodium diet/Renal impairmentPatients on a low sodium diet or who have renal impairment should be informed that the quantity of sodium in the maximum daily dose of CEPROTIN exceeds 200 mg. Monitor patients with renal impairment closely for sodium overload.

The common adverse reactions related to CEPROTIN treatment observed in clinical trials were the following hypersensitivity or allergic reactions: lightheadedness, itching and rash.


CEPROTIN® [Protein C Concentrate (Human)] is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans

Please review the CEPROTIN Prescribing Information for full prescribing details.


You are about to leave this Web site. Please be advised that Shire Pharmaceuticals has no control over the content or presentation of the site you are about to view. Shire's Privacy Policy does not apply to the Web site you are about to visit.

Cancel >